1. Home
  2. MLYS vs HGTY Comparison

MLYS vs HGTY Comparison

Compare MLYS & HGTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • HGTY
  • Stock Information
  • Founded
  • MLYS 2019
  • HGTY 1984
  • Country
  • MLYS United States
  • HGTY United States
  • Employees
  • MLYS N/A
  • HGTY N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • HGTY Specialty Insurers
  • Sector
  • MLYS Health Care
  • HGTY Finance
  • Exchange
  • MLYS Nasdaq
  • HGTY Nasdaq
  • Market Cap
  • MLYS 890.6M
  • HGTY 934.4M
  • IPO Year
  • MLYS 2023
  • HGTY N/A
  • Fundamental
  • Price
  • MLYS $14.89
  • HGTY $10.94
  • Analyst Decision
  • MLYS Strong Buy
  • HGTY Sell
  • Analyst Count
  • MLYS 4
  • HGTY 2
  • Target Price
  • MLYS $27.00
  • HGTY $10.00
  • AVG Volume (30 Days)
  • MLYS 869.6K
  • HGTY 256.1K
  • Earning Date
  • MLYS 08-12-2025
  • HGTY 08-04-2025
  • Dividend Yield
  • MLYS N/A
  • HGTY N/A
  • EPS Growth
  • MLYS N/A
  • HGTY 90.09
  • EPS
  • MLYS N/A
  • HGTY 0.20
  • Revenue
  • MLYS N/A
  • HGTY $1,303,397,000.00
  • Revenue This Year
  • MLYS N/A
  • HGTY $15.41
  • Revenue Next Year
  • MLYS N/A
  • HGTY $15.88
  • P/E Ratio
  • MLYS N/A
  • HGTY $53.74
  • Revenue Growth
  • MLYS N/A
  • HGTY 17.90
  • 52 Week Low
  • MLYS $8.24
  • HGTY $8.03
  • 52 Week High
  • MLYS $18.38
  • HGTY $12.35
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 55.68
  • HGTY 54.51
  • Support Level
  • MLYS $14.26
  • HGTY $10.67
  • Resistance Level
  • MLYS $15.55
  • HGTY $11.27
  • Average True Range (ATR)
  • MLYS 0.85
  • HGTY 0.46
  • MACD
  • MLYS 0.18
  • HGTY -0.01
  • Stochastic Oscillator
  • MLYS 77.53
  • HGTY 80.99

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About HGTY Hagerty Inc.

Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.

Share on Social Networks: